Periocular injection of candesartan-PLGA microparticles inhibits laser-induced experimental choroidal neovascularization
- PMID: 30643382
- PMCID: PMC6318708
- DOI: 10.2147/OPTH.S181110
Periocular injection of candesartan-PLGA microparticles inhibits laser-induced experimental choroidal neovascularization
Abstract
Purpose: Microparticle technology enables local administration of medication. The purpose of this study was to examine the inhibitory effect of locally administered candesartan (CAN)-encapsulated microparticles on experimental choroidal neovascularization (CNV).
Methods: Laser photocoagulation was used to induce CNV in Brown Norway rats. The rats were pretreated with subconjunctival injections of CAN (5.0 mg/eye) or phosphate buffer saline for 3 days before photocoagulation. The volume of CNV was evaluated 7 days after laser injury using the lectin staining technique. The infiltration of macrophages within the CNV lesion was determined using immunofluorescent staining with an anti-CD68 antibody. mRNA levels of MCP-1, IL1-β and VEGF in the retinal pigment epithelium/choroid complex were determined using quantitative PCR (q-PCR).
Results: CNV volume was significantly suppressed by the treatment with CAN compared with that in vehicle-treated eyes (P<0.05, two-tailed Student's t-test). Subconjunctival injections of CAN decreased the numbers of CD68+ cells in the CNV lesion. The increased mRNA levels of MCP-1, IL1-β, and VEGF induced by photocoagulation was significantly suppressed following the local administration of CAN (P<0.05, two-tailed Student's t-test).
Conclusion: Local administration of CAN inhibited experimentally induced CNV possibly through anti-inflammatory effects.
Keywords: age-related macular degeneration; candesartan; choroidal neovascularization; macrophage; monocyte chemotactic protein 1; poly(lactic-co-glycolic acid); renin-angiotensin system.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures



References
-
- Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375–413. - PubMed
-
- Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. - PubMed
-
- Friedman DS, O’Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous